Compare DFIN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | PCRX |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.0M |
| IPO Year | 2017 | 2010 |
| Metric | DFIN | PCRX |
|---|---|---|
| Price | $47.31 | $25.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $61.50 | $30.25 |
| AVG Volume (30 Days) | 262.4K | ★ 628.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 2.72 | 0.19 |
| Revenue | ★ $963,000,000.00 | $541,533,000.00 |
| Revenue This Year | $4.98 | $6.78 |
| Revenue Next Year | $3.87 | $8.54 |
| P/E Ratio | ★ $17.79 | $134.63 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $36.11 | $18.80 |
| 52 Week High | $58.45 | $27.66 |
| Indicator | DFIN | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 49.26 |
| Support Level | $44.20 | $22.03 |
| Resistance Level | $50.23 | $26.94 |
| Average True Range (ATR) | 2.55 | 1.04 |
| MACD | -0.30 | -0.13 |
| Stochastic Oscillator | 56.38 | 39.71 |
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.